COGT Stock: Price, Earnings History and SEC Filings
Cogent Biosciences, Inc. (COGT) last traded at $31.02, down 2.94% on the latest session and down 3.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.52 against an analyst estimate of $-0.55, a beat of 5.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
COGT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 10, 2026 | $-0.52 | $-0.55 | +5.45% |
| Mar 2026 | May 5, 2026 | $-0.53 | $-0.53 | +0.00% |
| Dec 2025 | Feb 17, 2026 | $-0.55 | $-0.51 | -7.84% |
| Sep 2025 | Nov 7, 2025 | $-0.50 | $-0.54 | +7.41% |
COGT beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How COGT reacts to earnings
Across its last 8 earnings releases, COGT moved 5.3% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-10 | Before open | -2.03% |
| 2026-05-05 | Before open | +0.68% |
| 2026-02-17 | Before open | +2.98% |
| 2025-11-03 | Before open | -4.91% |
| 2025-08-05 | Before open | -5.73% |
| 2025-07-10 | Before open | +4.33% |
| 2025-05-06 | Before open | -15.62% |
| 2025-02-25 | Before open | -6.30% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
COGT financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2020 | $8M | -$75M | – | -950.4% | – |
| 2019 | $22M | -$32M | -$42M | -141.5% | – |
| 2018 | $10M | -$35M | -$33M | -354.8% | – |
| 2017 | $8M | -$25M | -$27M | -304.9% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for COGT
- 8-K · Sep 2, 2026Material agreement
- 8-K · Aug 10, 2026Other events, Financial statements and exhibits
- 424B5 · Aug 10, 2026
- 10-Q · Aug 10, 2026
- 8-K · Aug 10, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 11, 2026Shareholder vote
- 10-Q · May 5, 2026
- 8-K · May 5, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 23, 2026
- 10-K · Feb 17, 2026
Insider filing activity
COGT insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
COGT news
- Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation ConferenceOct 27, 2026 · finance.yahoo.com
- Cogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?Oct 20, 2026 · finance.yahoo.com
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc. (COGT) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.